As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of ...

Sales for Lumakras and Blincyto in particular soared during the third quarter as the firm's overall revenues climbed 23 percent year over year.

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

Nuevolution has been developing small molecule drugs since it was founded in 2001, focused on targets within inflammation, oncology ... produce marketable products. Amgen added that it does ...

Amgen AMGN reported third-quarter ... more than offsetting declining revenues from oncology biosimilars and legacy established products such as Enbrel. The addition of Horizon products boosted ...

The company now counts on an extensive portfolio of blockbuster drugs across fields like oncology ... Beyond the products currently on the market, Amgen benefits from a pipeline of multiple ...

further strengthening Amgen's position in the oncology market. Enbrel, one of Amgen's established products, faces challenges in the Medicare Part D negotiations, with a 67% discount to list price.

Amgen Inc (AMGN) reports a 23% revenue increase, driven by strong product sales and promising developments in its innovative ...

Nuevolution has been developing small molecule drugs since it was founded in 2001, focused on targets within inflammation, oncology ... produce marketable products. Amgen added that it does ...